Fig 1.
Schematic of proposed pathways in which ticagrelor may affect S. aureus infection (not to scale): (1) enhancement of platelet-mediated S. aureus killing; (2) prevention of α-toxin–mediated platelet desialyation and subsequent removal from circulation via the hepatic Ashwell–Morell receptor; and (3) inhibition of S. aureus binding to host tissues via adhered platelets.